DOCSLIB.ORG

Alumni Newsletter Issue 9

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alumni Newsletter Issue 9 DEPARTMENT OF ENGINEERING SCIENCE NEWSLETTER ISSUE 9: 2019 INSIDE THIS ISSUE: 002 NEWS 010 OUR INSTITUTES 020 ALUMNA PROFILE Welcome from the new Head of Department News from the Oxford-Man Institute, Laura Mason, Legal & General Oxford e-Research Centre, Institute of Biomedical Engineering, Oxford Thermofluids Institute and Oxford Robotics Institute 004 RESEARCH NEWS 016 STUDENT NEWS 023 ACADEMIC NEWS Freak wave recreated in lab Meet our student ambassadors Our seven new academics AI helping to identify cancer cells DEPARTMENT OF 002 ENGINEERING SCIENCE NEWS WELCOME Welcome from the Head of Department speciality is physical acoustics – the The latest avenue for opportunity physics of sound – and the application of is space, as in new buildings and physical acoustics principles to problems laboratories. In the coming years, I hope in biomedical acoustics, industrial to be able to share exciting news about ultrasonics, and acoustical oceanography. new buildings and facilities designed However, my true passion is the to enhance our research capability and acoustics of bubbles and bubbly media. overall ability to deliver a 21st century Sonoluminescence (light from sound), course. acoustic cavitation dynamics, shock- driven cavity collapse physics, and There are many other research bubble-mediated therapeutic ultrasonics highlights from the Department in this are topics of past and current interest. newsletter, but I would draw your attention I have thoroughly enjoyed my time in to the news item on First Light Fusion, Oxford and look forward to leading the one of the many exciting spinouts from department in a period of continued our research. They are endeavouring to growth and opportunity. solve one of the world most compelling and difficult problems: how to induce Under Lionel’s leadership, the controlled inertially confined fusion for department has expanded substantially power generation. The company is a and either established or consolidated shining example of how universities can world leading positions in a number of deliver impact today as well as help shape exciting fields, including multiple aspects the future. In my first welcoming message as the of information engineering, biomedical new Head of Department, I am pleased engineering, and turbomachinery. We Finally, I would like to highlight the fact to announce that Oxford’s Department of have expanded our portfolio to include the that the 46th Maurice Lubbock Lecture will Engineering Science continues to excel new Oxford Suzhou Centre for Advanced feature Dr Anita Sengupta, an aerospace in the international engineering league Research in China. We have won a engineer and veteran of the US space table, earning a 5th ranking worldwide number of high-profile professorships program who spent 16 years at NASA and after having ranked #1 in 2018. Although sponsored by the Royal Society and is now Co-Founder and CPO at Airspace this is technically a drop in our ranking, the Royal Academy of Engineering and Experience Technologies (ASX), which is the scoring differential between 1st consolidated 5 research Institutes within developing urban aerial mobility solutions and 5th place is exceedingly small. the Department. Innovation has been a key based on emission-free autonomous VTOL Engineering Science continues to reside aspect of our portfolio, with over 30 new technology. I hope to see many of you at in the very highest echelon of engineering spinouts originating from the Department her lecture on Thursday 4th June 2020 at departments across the globe. This is a in the past 4-5 years. We have expanded Pembroke College. huge accolade for the Department and a the undergraduate course to include new wonderful endorsement of our teaching, offerings in Biomedical and Information Professor Ronald A. Roy research and innovation. I congratulate Engineering. We have helped set up the students, researchers, staff, and successful MSc in Energy Systems and academics who make this happen. Nanotechnology. In addition, I would like to offer my thanks and congratulations to Professor Lionel Tarassenko - thanks for doing such an outstanding job as Head of Department over the past five years, and Front cover images congratulations for being named the first Top Right: Doctoral student Damien Frost, working Bottom Left: Rhodes Scholar Naomi Mburu's Head of House of Parks College, a new with Professor David Howey, tests his patented DPhil research aims to study the practicality of Oxford graduate college established in control algorithm for a ‘smart battery system’ that using liquid metal walls on the inside of nuclear the past year. Lionel will continue to play uses distributed power converters to improve fusion reactors. Her work specifically involves a prominent role in the Department while battery life and performance in applications such experimentally and computationally quantifying leading the College, and we wish him the as grid energy storage systems. This is now being flow patterns of liquid metals in nuclear fusion very best of luck with this exciting new used by University spin-out Brill Power Ltd. reactor relevant conditions. Image by John project. Russell, Vanderbilt University. Top Left: Oxford University spinout First Light For those of you who don’t know me, I Fusion is researching energy generation by inertial Bottom Right: Crystalline (red) and amorphous am a relative newcomer to Oxford. After confinement fusion using Machine 3, the biggest (green) phase of ZIF-8 crystals, variations of spending 26 years as a researcher in pulsed power machine in the world. Image shows Metal-Organic Framework (MOF) crystals, a industry and an academic in four different a top view of Machine 3 showing the vacuum emergent class of hybrid materials used in gas research universities dotted across the chamber and five of the six “limbs” with their absorption and separation, guest encapsulation, US, I joined Oxford in 2013 as the Professor capacitor banks and transmission lines. and drug delivery. Image by Barbara Souza. of Mechanical Engineering. My research DEPARTMENT OF NEWS AND EVENTS ENGINEERING SCIENCE NEWS 003 The 46th Maurice Lubbock From Flying Memorial Lecture 2020 Cars to Humans on Mars - The The Lubbock Lecture will be held at She worked for NASA for 16 years Pembroke College on 4th June 2020, from where her engineering projects included 5-6pm (followed by a drinks reception). her PhD research on developing the ion Future of We are pleased to welcome rocket propulsion system for the Dawn Mission, scientist and aerospace engineer Dr Anita the supersonic parachute that landed the Transportation Sengupta. Dr. Sengupta is an aerospace Curiosity rover on Mars, and the Cold Atom engineer, rocket scientist, pilot, and Laboratory - an atomic physics facility now veteran of the space program. on board the International Space Station. In the global marketplace that transfers knowledge at the speed of light, we have a massive time delay that is modern transportation methods. We each spend up to 30% of our lives commuting on congested freeways, airports, and train stations. We put greenhouse gases into the atmosphere and change our climate with global consequences to health, habitat loss, and our economic future. On the cargo front this results in lost revenue and productivity, with no clear path to address the growing demands of the global market place. What if we could disrupt transportation, an aging and non-agile industry which has not seen a new mode in over 100 years. By introducing game changing technologies we can increase capacity, enhance energy efficiency, and shrink our carbon footprint. Dr. Sengupta will discuss how space- age tech coupled to the VC funded innovation environment are enabling the revolution in green transportation. She will share her real-world engineering projects from her work developing the world’s first hyperloop in Las Vegas Nevada, to autonomous VTOL air taxis her new Anita Sengupta company is designing in Detroit Michigan, to her research on entry systems that will land the first humans on Mars. CONTENTS Alumni Weekend and Welcome from the new Head of Department 2 Research News 4 Jenkin Lecture Our Institutes 8 As part of the 2020 Oxford University Alumni Weekend Entrepreneurship 12 (11th-13th September 2020) we will hold the annual Jenkin Outreach and Public Engagement 14 Lecture on Saturday 12th September – the speaker will be announced nearer the time. Student News 16 Alumna Profile 20 There will also be the chance to meet academics from the Alumni News 21 Department and fellow alumni over drinks and canapés. Academic News 23 For more information and to register for these events visit www.eng.ox.ac.uk/events DEPARTMENT OF 004 ENGINEERING SCIENCE NEWS RESEARCH NEWS Famous freak wave recreated in laboratory mirrors Hokusai’s ‘Great Wave’ Researchers have recreated for the first time the famous Draupner freak wave. Measured in the North Sea in 1995, it was one of the first confirmed observations of a freak wave in the ocean. Freak waves are unexpectedly large in comparison to surrounding waves. They are difficult to predict and are commonly attributed as probable causes for maritime catastrophes such as the sinking of large ships. A team of researchers led by Oxford engineers Dr Mark McAllister and Professor Ton van den Bremer, in collaboration with Professor Thomas Adcock (University of Oxford) and Dr Sam Draycott at the University of Edinburgh, set out to reproduce the Draupner wave under laboratory conditions. They successfully reconstructed the The laboratory recreation of the Draupner wave. Image: McAllister, M.L. et al. J. Fluid Mech. (2019); CC BY 4.0 wave using two smaller wave groups and varying the ‘crossing angle’ – the angle state-of-the-art understanding of ocean over Mount Fuji, which appears in the at which the two groups travel. The wave breaking." background. researchers found it was only possible to reproduce the freak wave when the To the researchers’ surprise, the wave The researchers hope this study will lay crossing angle was approximately 120 they created in the lab bore an uncanny the groundwork for being able to predict degrees.
Load more

Recommended publications
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Rt Hon Boris Johnson Prime Minister 10 Downing Street London SW1A 2AA
    Rt Hon Boris Johnson Prime Minister 10 Downing Street London SW1A 2AA 29 November 2019 Dear Prime Minister, We are writing as 350 members of the climate change research community in the United Kingdom to urge you to challenge robustly the President of the United States of America, Donald Trump, during his visit to the United Kingdom next week about his reckless approach to climate change and his false claims about the Paris Agreement. The United Kingdom is likely to be confirmed next month at the United Nations climate change summit in Madrid as the host of the 26th session of the Conference of the Parties (COP26) to the United Nations Framework Convention on Climate Change in 2020. Next year’s summit, which your Government has indicated will take place in Glasgow, will be absolutely vital to international efforts to avoid dangerous climate change. Parties to the Paris Agreement are expected to submit ahead of the summit revised nationally determined contributions which include more ambitious pledges to reduce annual emissions of greenhouse gases. The United Kingdom has been attempting to lead by example on climate change and has reduced its annual production of emissions of greenhouse gases by 44 per cent between 1990 and 2018, while increasing its gross domestic product by about 75 per cent over the same period. The United Kingdom’s consumption emissions have also started to decline. Although the United Kingdom is currently not on track to meet its fourth and fifth carbon budgets, according to the Committee on Climate Change, the UK Government made a very significant advance on domestic policy earlier this year by successfully securing the passage of legislation through Parliament to strengthen the Climate Change Act such that the new target is to reduce annual emissions of greenhouse gases to net zero by 2050.
    [Show full text]
  • Appointments Education Research Interests Honors and Recognition
    Josef Dufek Gwen and Charles Lillis Chair Department of Earth Sciences Associate Member, Knight Campus for Accelerating Scientific Impact University of Oregon Eugene, OR 97403-1272, USA [email protected] Appointments 2006-2008 Miller Postdoctoral Fellow, University of California, Berkeley 2008-2013 Assistant Professor, School of Earth and Atmospheric Science, Georgia Institute of Technology 2012-2014 Blanchard-Milliken Young Faculty Chair, Georgia Institute of Technology 2013-2016 Associate Professor, School of Earth and Atmospheric Science, Georgia Institute of Technology 2016 - 2018 Professor, School of Earth and Atmospheric Science, Georgia Institute of Technology 2014-2018 Associate Chair, School of Earth and Atmospheric Science, Georgia Institute of Technology 2018 – Gwen and Charles Lillis Chair, Director of the Center for Volcanology, Department of Earth Sciences, University of Oregon 2020 – Associate Member, Knight Campus for Accelerating Scientific Impact 2019 - Visiting Scientist, Lawrence Livermore National Laboratory Education University of Washington, Department of Earth and Space Sciences, Seattle, WA Ph.D. in Earth and Space Sciences, 2006. Thesis: The Ascent and Eruption of Arc Magmas: A Physical Examination of the Genesis, Rates, and Dynamics of Silicic Volcanism. (Advisor George Bergantz) University of Washington, Department of Earth and Space Sciences, Seattle, WA M.S. in Geology, 2004. Thesis: Lower Crustal Magma Genesis and Preservation: A Stochastic Framework for the Evaluation of Basalt-Crust Interaction (Advisor George Bergantz) University of Chicago, Department of Geophysical Sciences, Chicago, IL B.S. with Honors in Geophysical Sciences, 2000. Honors Thesis: A Coupled Dynamic Glacier-Atmosphere Model of the Climate of Early Mars (Advisor Raymond Pierrehumbert) Research Interests Turbulent multiphase flow, comparative planetology, natural hazards, physical petrology, explosive eruption dynamics, magma dynamics, mass and heat transfer in the crust and geochemical consequences, and planetary volcanism.
    [Show full text]
  • GPC NEWSLETTER Issue #5
    GPC NEWSLETTER Issue #5 5 GPC Newsletter March 2016 IN THIS ISSUE APS TOPICAL GROUP ON THE PHYSICS OF CLIMATE Welcome from the Chair Message from the Editor Juan Restrepo, Oregon State University This is the fifth GPC Newsletter, timed as often the case with the APS March Meeting. Page 1 We have now increased the frequency of the Newsletter to twice per year, and this is where you, the GPC membership, can be of enormous value. We invite comments, GPC 2016: Executive event notices, letters, and especially specific suggestions for content. Any of the above, Page 2 addressed to [email protected], will be gratefully acknowledged in a timely fashion. GPC 2016: Committees Pages 3, 4, 8 Welcome from the GPC Chair, Juan Restrepo, Oregon State University Continued on p. 2 2016 APS March Meeting Sessions I am employed by a mathematics department, but I do have a license to practice physics. I work on the role played by oceans on climate. I also work on devising computational methods GPC Climate Science Café, GPC Invited that yield forecasts and retrodictions using data and evolutionary models, taking into account and Focus sessions their inherent uncertainties. There is little doubt in my mind that my background in physics Pages 3-8 has equipped me well with the skills I need to make inroads in climate science. It turns out that there are a significant number of very good scientists who work in climate science that Upcoming Events and Other also have a physics background. Links of Interest The APS offers, through its members, an amazing array of talent and technical expertise, and Page 9 a fresh perspective, with the potential of making impressive contributions to advancing the relatively young science of climate.
    [Show full text]
  • 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug Erik De Clercq
    j1 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug Erik De Clercq 1.1 Introduction: The Prehistory More than 50 years ago, the synthesis of IDU (iododeoxyuridine), a thymidine analogue, was described by Prusoff [1]. This compound would later become the first antiviral drug to be licensed for (topical) use in the treatment of herpes simplex virus (HSV) infections of the eye. In this sense, the advent of IDU marked the birth of the antiviral drug era. There are now about 50 licensed antiviral compounds, half of them are used for the treatment of AIDS, of which the viral origin was first recognized 27 years ago [2, 3] (2008 Nobel Prize for Medicine or Physiology was awarded to Fran¸coise Barre-Sinoussi and Luc Montagnier for their discovery of human immu- nodeficiency virus and to Harald zur Hausen for demonstrating the link between human papilloma virus (HPV) and cervical cancer). Was IDU truly the first antiviral? In retrospect, the antiviral chemotherapy era had a rather slow and unremarkable start. The first compounds quoted to have antiviral activity (against vaccinia virus) were the thiosemicarbazones [4, 5]. These compounds were also found effective against vaccinia virus infection in mice and rabbits [6–8], and one of the thiosemicarbazones, that is, N-methylisatin-b-thiosemicarbazone, even entered clinical studies for the prophylaxis of smallpox [9] just when the smallpox vaccination took over and made any further attempts to develop an antipoxvirus drug apparently superfluous. Then came the benzimidazole derivatives as inhibitors of influenza virus multi- plication [10, 11], but despite the reported effectiveness of the 5,6-dichloro-1-b-D- ribofuranosyl benzimidazole (DRB) [10, 11] against influenza virus multiplication, it was not pursued further as a potential anti-influenza virus agent.
    [Show full text]
  • DNA Methylation Patterns and Cancer
    restriction/modification system, which brought Werner Arber, Daniel Nathans and Hamilton Smith the 1978 Nobel Prize in Physiology or Medicine, and made restriction enzymes the primary tools of Charles Rodolphe Brupbacher Foundation molecular biology. Four decades have passed since then, but the role of 5-methylcytosine in eukaryotic DNA metabolism is still shrouded in mystery. We know that the sperm methylation pattern is largely The erased after fertilization and that methylation is gradually reintroduced Charles Rodolphe Brupbacher Prize during embryogenesis and differentiation, but the processes that for Cancer Research 2017 regulate the cell type- and tissue-specific methylation patterns remain is awarded to to be elucidated. We have also learned that DNA can be not only methylated, but also demethylated, and that aberrant methylation can lead to disease - including cancer. Again, how these processes are regulated remains to be discovered. However, we have learnt a great Sir Adrian Peter Bird, deal about 5-methylcytosine metabolism during the past three decades and much of our knowledge came from the laboratory of Adrian Bird. PhD Adrian spent his doctoral and postdoctoral time in Max Birnstiel’s for his contributions to our understanding laboratory, first in Edinburgh and then in Zurich, studying the amplification of ribosomal DNA in Xenopus laevis. In this organism, of the role of DNA methylation in genomic rDNA in somatic tissues is highly methylated, while the development and disease extrachromosomal amplicons are unmethylated. When he returned to Edinburgh to establish his own group, Adrian set out to study The President The President of the Foundation of the Scientific Advisory Board the methylation pattern of these loci using the newly-available methylation-sensitive restriction enzymes.
    [Show full text]
  • FULL BOARD MEETING September 26, 2019, 8:30AM Chancellor's
    FULL BOARD MEETING September 26, 2019, 8:30AM Chancellor’s Ballroom, Carolina Inn OPEN SESSION 1. Convene Meeting 2. Roll Call 3. Consent Agenda a. Approval of July 31-August 1, 2019 Minutes (Regular Meeting) b. Ratification of Mail Ballot dated June 6, 2019 c. Ratification of Mail Ballot dated August 13, 2019 d. Ratification of Mail Ballot dated September 12, 2019 4. Chair’s Remarks 5. Student Body President’s Remarks 6. Chancellor’s Remarks 7. Environment, Ecology, and Energy Program – Dr. Jaye Cable, Senior Associate Dean for Natural Sciences and Mathematics and Professor, Department of Marine Sciences, & Dr. Paul Leslie, Chair, Environment and Ecology and Pardue Distinguished Professor, Department of Anthropology 8. UNC Policy Collaboratory – Dr. Jeff Warren, Research Director 9. Report of the External Relations Committee 10. Report of the Finance, Infrastructure & Audit Committee 11. Report of the University Affairs Committee CLOSED SESSION 12. *Report of the University Affairs Committee 13. *Legal Update OPEN SESSION 14. Report of the University Affairs Committee 15. Adjournment *Some of the business to be conducted is authorized by the N.C. Open Meetings Law to be conducted in closed session. BOARD OF TRUSTEES MEETING The University of North Carolina at Chapel Hill August 1, 2019 The Board of Trustees met in regular session on Thursday, August 1, 2019 at The Carolina Inn, Chancellor’s Ballroom. Chair Stevens convened the meeting at 8:32 a.m. ROLL CALL Trustee Artis Neal called the roll and the following members were present: Teresa Artis Neal Ashton B. Martin David L. Boliek, Jr. Allie Ray McCullen Jefferson W.
    [Show full text]
  • View Annual Report
    Connecting... Annual Report 2001 Mission Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer. Our Spirit We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Strategic Intent We want to become the indisputable leader in our industry. GlaxoSmithKline plc is an English public limited company. Its shares are listed on the London Stock Exchange and the New York Stock Exchange. GlaxoSmithKline plc acquired Glaxo Wellcome plc and SmithKline Beecham plc on 27th December 2000 by way of a scheme of arrangement for the merger of the two companies which became effective on 27th December 2000. This report is the Annual Report of GlaxoSmithKline plc for the year ended 31st December 2001. It comprises in a single document the Annual Report of the company in accordance with United Kingdom requirements and the Annual Report on Form 20-F to the Securities and Exchange Commission in the United States of America. A summary report on the year, the Annual Review 2001, intended for the investor not needing the full detail of the Annual Report, is produced as a separate document. The Annual Review includes the joint statement by the Chairman and Chief Executive Officer, a summary review of operations, summary financial statements and a summary remuneration report. The Annual Review is issued to all shareholders.
    [Show full text]
  • Investor Information 2014
    Investor information reportStrategic In this section Quarterly trend 218 Five year record 222 Product development pipeline 225 Products, competition and intellectual property 229 Risk factors 232 Share capital and share price 242 remuneration & Governance Dividends 244 Tax information for shareholders 244 Annual General Meeting 2015 245 US law and regulation 247 Shareholder services and contacts 249 Glossary of terms and index 251 Financial statementsFinancial Investor information Investor GSK Annual Report 2014 217 Financial record Strategic reportStrategic Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2014. Income statement – total 12 months 2014 Q4 2014 £m CER% £% £m CER% £% Turnover – Pharmaceuticals and Vaccines 18,670 (6) (12) 5,070 (7) (10) – Consumer Healthcare 4,336 (11) (18) 1,116 (7) (10) Total turnover 23,006 (7) (13) 6,186 (7) (10) Cost of sales (7,323) (11) (15) (2,029) (18) (20) Selling, general and administration (8,246) 4 (3) (2,207) 4 – Research and development (3,450) (8) (12) (979) (7) (9) Royalty income 310 (18) (20) 67 (31) (32) Other operating income (700) (347) Operating profit 3,597 (40) (49) 691 (69) (72) Governance & remuneration & Governance Net finance costs (659) (171) Profit on disposal of interest in associates and joint ventures – – Share of after tax profits of associates and joint ventures 30 11 Profit before taxation 2,968 (46) (55) 531 (77) (79) Taxation (137) 494 Tax rate % 4.6% (93.0)% Profit after taxation for the period 2,831 (41) (50)
    [Show full text]